Q/A session10 Jun 2025 11:38
Q3 - Why would shareholders expect results in AVA6103 in less than one year?
CC "Well, it's because we know what are those disease settings that we should be going into.
We know where the topo 1 mechanism is active and we expect to see activity in those cohorts.
So instead of an empiric search for what are the disease settings, we’ve leveraged AI, and used it to drive much smarter trials.
There is a lot of buzz and we have a number of sites that are quite excited about FAP dox and they are all asking for the FAP exetecan to be held at their clinical trial sites.
We aren’t going to have to convince investigators. We are excited about moving this one forward.
I think we are making a bold prediction that we are going to be able to get this trial moving very quickly.
It’s really leveraging AI, but also leveraging those key relationships that we have with a number of great medical centers.
We have opened MD Anderson in US as our third site here. We have Memorial Sloan Kettering, the Christy, we have fantastic clinical trial sites, and all of them have asked to be able to participate in FAP exetecan.
It’s both AI, but also leveraging those relationships we have."
++++
So medical centers are excited, wanting to host AVA6103 trials.
++++
If medical centers are excited, BP will be just as excited / more so - and dependent on fresh trial data visibility.
Don't allow detractors to sew doubts here.
If certain medical centers are not selected to host trials, it won't hurt their bottom line, but will hurt their prestige.
If certain BP do not end up using preCISION, the default is they will be developing ADC's, effectively waiting for the next bus.
The BP that will have preCISION in their product catalogue will have gained a large competitive edge, and will have to buy Avacta to enjoy it's benefits.
Throw in that preCISION development costs are one tenth the cost of ADC development, and you arrive at a much better understanding of the term competitive advantage, transforming a want into a need for platform ownership.
Interested BP (why wouldn't there be many) are going to be very concerned if their PDC future does not contain preCISION, unless they enter a JV with the IP holder.
++++
I feel BP will want to settle the issue of IP and platform ownership sooner rather than later, probably after successful phase 1b results.
Everyone will want to see trials progressing faster in future, as per a larger BP budget.
Money. Any better arrangement than we have now with the CLN can only improve Avacta's position.
I feel a better financial footing is more of a possibility now for Avacta, after the arrival of two new NED's.
Sign In
Follow the stocks
